Cover Image
市場調查報告書

美國的生物學性、組織工程設備 - 心血管及神經學性產品

U.S. Markets for Biologic and Tissue Engineered Devices - Cardiovascular and Neurological Products

出版商 Medtech Insight 商品編碼 327399
出版日期 內容資訊 英文 110 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
美國的生物學性、組織工程設備 - 心血管及神經學性產品 U.S. Markets for Biologic and Tissue Engineered Devices - Cardiovascular and Neurological Products
出版日期: 2015年03月27日 內容資訊: 英文 110 Pages
簡介

組織工程或再生醫療成為侵佔性疾病或致死疾病的有潛力治療方法。特別是心血管疾病和神經疾病的細胞療法是搖錢樹市場。現在超過35種細胞療法在美國為首的各國開發。

本報告提供心血管疾病及神經疾病的新興細胞療法、開發新的細胞療法的企業概要、現在開發中細胞療法產品的法律規章認證取得預測、市場分析與未來預測等彙整資料。

第1章 組織工程和細胞療法工具及技術

  • 生醫材料
    • 生物來源的生醫材料
    • 基因改造生醫材料
    • 混合生醫材料
    • 合成生醫材料
    • 支架
    • 血管
  • 細胞培養技術
    • 生物反應器
  • 幹細胞技術
  • 免疫隔離技術

第2章 心血管疾病管理上組織工程及細胞移植的新興應用

  • 細胞療法與組織工程
  • 細胞療法的給藥
  • 幹細胞為基礎的心肌組織修復和再生臨床實際成果
  • 開發中心肌組織修復與再生的細胞療法
  • 重度的肢體缺血患者的保肢用新興細胞療法
  • 生物工程血管
  • 現行及新興美國的心血管相關組織工程和細胞療法產品市場

第3章 神經疾病管理上的組織工程及細胞移植的新興應用

  • 開發中細胞療法所採用的細胞種類
  • 老年癡呆症的新興幹細胞為基礎治療方法
    • 老年癡呆症的開發中細胞療法
    • 法律規章計劃
  • 帕金森氏症的新興幹細胞為基礎治療方法
    • 帕金森氏症的開發中細胞療法
    • 法律規章計劃
  • 脊髓損傷的新興幹細胞為基礎治療方法
    • 脊髓損傷的開發中細胞療法
    • 法律規章計劃
  • 缺血性中風後的新興幹細胞為基礎治療方法
    • 缺血性中風的開發中細胞療法
    • 法律規章計劃
  • 美國的神經疾病相關細胞療法產品市場

附錄:企業清單

參考文獻

目錄
Product Code: A427

Tissue engineering, or regenerative medicine, represents a promising therapeutic possibility for the treatment of aggressive and deadly diseases. Cellular therapies for cardiovascular disease (CVD) and neurological disease represent potential billion dollar markets that could offer a viable therapeutic option for a sizable patient population that has exhausted other therapeutic alternatives. Over 35 novel cellular therapies for cardiovascular and neurological disease are currently in development internationally, and in the United States (U.S.).

Content included in this report includes:

  • emerging cellular therapies for cardiovascular and neurological diseases;
  • companies and biotech firms developing novel cellular therapies;
  • a prospective regulatory approval forecast for cellular therapy products currently in development for cardiovascular and neurological diseases; and,
  • a speculative market analysis predicting the potential overall market values for cardiovascular and neurological disease stem cell therapies.

The scope of the analysis of this report covers companies developing novel cellular therapeutics for the treatment of debilitating and deadly diseases that currently lack adequate therapeutic intervention. Cardiovascular disease-related conditions with cellular therapies in development are discussed in Chapter 2 of this report, which covers acute myocardial infarction, critical limb ischemia, heart failure, and bioengineered vascular grafts. Neurological conditions/diseases discussed in Chapter 3 of this report include Alzheimer's disease, ischemic stroke, Parkinson's disease, and spinal cord injury.

Table of Contents

EXECUTIVE SUMMARY

  • i. Methodology

1. TISSUE ENGINEERING AND CELLULAR THERAPY TOOLS AND TECHNIQUES

  • 1.1. Biomaterials
    • 1.1.1. Biologically Derived Biomaterials
      • 1.1.1.1. Collagen
      • 1.1.1.2. Xenogenic Tissue
    • 1.1.2. Genetically Engineered Biomaterials
      • 1.1.2.1. Deoxyribonucleic Acid Transfection Vectors
      • 1.1.2.2. Genetically Manipulated Cells
      • 1.1.2.3. Three-Dimensional Polymer Technology
      • 1.1.2.4. Transgenics
      • 1.1.2.5. Fibroblasts
      • 1.1.2.6. Immortalized Neural Stem Cells
      • 1.1.2.7. Gene Activated Matrices
    • 1.1.3. Hybrid Biomaterials
    • 1.1.4. Synthetic Biomaterials
    • 1.1.5. Scaffolds
    • 1.1.6. Vascular Grafts
  • 1.2. Cell Culture Technology
    • 1.2.1. Bioreactors
      • 1.2.1.1. Flatbed Perfusion Systems
      • 1.2.1.2. Hollow Fiber Bioreactor Systems
      • 1.2.1.3. Cell Suspension Systems
      • 1.2.1.4. Disposable Bioreactors
  • 1.3. Stem Cell Technology
    • 1.3.1. Cell Extraction and Expansion
  • 1.4. Immunoisolation Technology
    • 1.4.1. Chimeric Immunity
    • 1.4.2. Cell Encapsulation Technology

2. EMERGING APPLICATIONS OF TISSUE ENGINEERING AND CELL TRANSPLANTATION IN CARDIOVASCULAR DISEASE MANAGEMENT

  • 2.1. Cellular Therapy and Tissue Engineering
    • 2.1.1. Skeletal Myoblasts
    • 2.1.2. Bone Marrow-Derived Stem Cells
    • 2.1.3. Adipose Tissue-Derived Stem Cells
    • 2.1.4. Cardiac Stem Cells
    • 2.1.5. Human Embryonic Stem Cells
    • 2.1.6. Induced Pluripotent Stem Cells
  • 2.2. Cellular Therapy Administration
  • 2.3. Clinical Experience with Stem Cell-Based Myocardial Tissue Repair and Regeneration
  • 2.4. Cellular Therapies for Myocardial Repair and Regeneration in Development
    • 2.4.1. Athersys
    • 2.4.2. Baxter
    • 2.4.3. Bioheart, Inc.
    • 2.4.4. Capricor Therapeutics
    • 2.4.5. Cytori Therapeutics
    • 2.4.6. Mesoblast Ltd.
    • 2.4.7. NeoStem
    • 2.4.8. Osiris Therapeutics
    • 2.4.9. Terumo Corporation
    • 2.4.10. Vericel
    • 2.4.11. Conceivable Regulatory Timetable
  • 2.5. Emerging Cellular Therapies for Limb Salvage in Critical Limb Ischemia Patients
    • 2.5.1. Therapeutic Angiogenesis
      • 2.5.1.1. Growth Factor/Gene-Based Angiogenic Therapy
      • 2.5.1.2. Stem Cell-Based Angiogenic Therapy
      • 2.5.1.3. Therapeutic Angiogenesis Products in Development
        • 2.5.1.3.1. Biomet Biologics
        • 2.5.1.3.2. Harvest Technologies
        • 2.5.1.3.3. Pluristem Therapeutics
        • 2.5.1.3.4. Taxus Cardium Pharmaceuticals Group
      • 2.5.1.4. Conceivable Regulatory Timetable
  • 2.6. Bioengineered Vascular Conduits
    • 2.6.1. Products in Development
    • 2.6.2. Conceivable Regulatory Timetable
  • 2.7. Current and Emerging U.S. Market for Cardiovascular Disease-Related Tissue Engineering and Cellular Therapy Products
  • Exhibit 2-1: Comparative Advantages and Disadvantages of Selected Stem Cell Grafts for Myocardial Repair and Regeneration
  • Exhibit 2-2: Selected Myocardial Cellular Repair and Regeneration Therapies in Development
  • Exhibit 2-3: Estimated Growth of Potential Myocardial Cellular Repair and Regeneration Caseloads, U.S., 2017-2020
  • Exhibit 2-4: Estimated Growth of Potential Therapeutic Angiogenesis Cellular Therapy Caseloads, U.S., 2017-2022
  • Exhibit 2-5: Estimated Growth of Potential Bioengineered Vascular Graft Caseloads, U.S., 2017-2022
  • Exhibit 2-6: Tissue Engineered Cardiac and Vascular Products, Expected Product Launch, by Indication
  • Exhibit 2-7: Tissue Engineered Cardiac and Vascular Products, Estimated Market Forecast, 2017 and 2022

3. EMERGING APPLICATIONS OF TISSUE ENGINEERING AND CELL TRANSPLANTATION IN NEUROLOGICAL DISEASE MANAGEMENT

  • 3.1. Types of Cells Used for Cellular Therapies in Development
    • 3.1.1. Bone Marrow-Derived Stem Cells
    • 3.1.2. Adipose Tissue-Derived Stem Cells
    • 3.1.3. Embryonic Stem Cells
    • 3.1.4. Induced Pluripotent Stem Cells
    • 3.1.5. Mesenchymal Stem Cells
    • 3.1.6. Neural Stem Cells
  • 3.2. Emerging Stem Cell-Based Therapies for Alzheimer's Disease
    • 3.2.1. Cellular Therapies in Development for Alzheimer's Disease
      • 3.2.1.1. Chinese Academy of Military Medical Sciences
      • 3.2.1.2. Medipost
      • 3.2.1.3. Neuralstem
      • 3.2.1.4. StemCells, Inc.
    • 3.2.2. Conceivable Regulatory Timetable
  • 3.3. Emerging Stem Cell-Based Therapies for Parkinson's Disease
    • 3.3.1. Cellular Therapies for Parkinson's Disease in Development
      • 3.3.1.1. Bundang CHA Hospital
      • 3.3.1.2. Fondazione IRCCS Ca'Granda, Ospedale Maggiore Policlinico
      • 3.3.1.3. Instituto de Medicina Regenerativa/Ageless Regenerative Institute
      • 3.3.1.4. International Stem Cell Corporation
      • 3.3.1.5. Neuralstem
    • 3.3.2. Conceivable Regulatory Timetable
  • 3.4. Emerging Stem Cell-Based Therapies for Spinal Cord Injury
    • 3.4.1. Spinal Cord Injury Cellular Therapies in Development
      • 3.4.1.1. Bukwang Pharmaceutical
      • 3.4.1.2. The General Hospital of Chinese Armed Police Forces
      • 3.4.1.3. Hospital Sao Rafael
      • 3.4.1.4. Neuralstem
      • 3.4.1.5. Neurogen Brain and Spine Insitute
      • 3.4.1.6. Pharmicell
      • 3.4.1.7. StemCells, Inc.
      • 3.4.1.8. Translational Biosciences
    • 3.4.2. Conceivable Regulatory Timetable
  • 3.5. Emerging Stem Cell-Based Therapies for Post-Ischemic Stroke
    • 3.5.1. Stem Cell Therapies for Ischemic Stroke in Development
      • 3.5.1.1. Athersys
      • 3.5.1.2. Ecron Acunova
      • 3.5.1.3. International Stem Cell Corporation
      • 3.5.1.4. Pharmicell
      • 3.5.1.5. ReNeuron, Ltd.
      • 3.5.1.6. SanBio
      • 3.5.1.7. Stemedica
      • 3.5.1.8. Stempeutics
      • 3.5.1.9. University of Irvine
    • 3.5.2. Conceivable Regulatory Timetable
  • 3.6. Potential U.S. Market for Neurological Disease-Related Cellular Therapy Products
  • Exhibit 3-1: Estimated Growth of Potential Early-Stage Alzheimer's Cellular Therapy Caseloads, U.S., 2015-2020
  • Exhibit 3-2: Estimated Growth of Early-Stage Parkinson's Disease Cellular Therapy Caseloads, U.S., 2015-2020
  • Exhibit 3-3: Estimated Growth of Potential Spinal Cord Injury Cellular Therapy Caseloads, U.S., 2015-2020
  • Exhibit 3-4: Estimated Growth of Potential Ischemic Stroke Cellular Therapy Caseloads, U.S., 2015-2020
  • Exhibit 3-5: Tissue Engineered Neurological Disease Products, Expected Product Launch, by Indication
  • Exhibit 3-6: Tissue Engineered Neurological Disease Products, Estimated Market Forecast, 2020

APPENDIX: COMPANY LISTING

BIBLIOGRAPHY

Back to Top